Gani Federica, Lombardi Carlo, Barrocu Laura, Landi Massimo, Ridolo Erminia, Bugiani Massimo, Rolla Giovanni, Senna Gianenrico, Passalacqua Giovanni
Allergy Service, Azienda Ospedaliera "San Luigi Orbassano", Turin, Italy.
2Departmental Unit of Allergology & Respiratory Diseases, Fondazione Poliambulanza, Brescia, Italy.
Clin Mol Allergy. 2018 Feb 2;16:4. doi: 10.1186/s12948-018-0082-y. eCollection 2018.
Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general population is affected, and in Italy the prevalence is estimated to be 19.8%. The Allergic Rhinitis and its Impact on Asthma (ARIA) international document underlined that the prevalence of severe or refractory or overlapping rhinitis is increasing and represents a non-negligible socio-economic burden. In general, despite the social healthcare costs, allergic rhinitis remains underestimated, not sufficiently controlled and often undertreated.
In this multi-center Italian observational and prospective study we assessed the control of AR in patients (> 16 years) without previous asthma diagnosis, referred to Allergy Centers.
Patients of both sexes and older than 16 with rhinitis symptoms and without asthma were studied. A Visual Analogue Scale (VAS) and the CARAT (Control of Allergic Rhinitis and Asthma Test) were used as patient reported outcome. The possible causes of poor control of AR, as per protocol, were assessed accordingly.
We observed 250 patients in a real-life setting: more than 60% of them had an uncontrolled AR, only about 50% used multiple medications, and only a minority were receiving allergen immunotherapy.
This survey, conducted in a real-life setting, confirmed that AR is overall poorly controlled. The VAS assessment well correlates with the structured CARAT questionnaire and with the relevant symptoms of AR.
变应性鼻炎(AR)是一种高发性疾病。在欧洲,约25%的普通人群受其影响,在意大利,患病率估计为19.8%。变应性鼻炎及其对哮喘的影响(ARIA)国际文件强调,重度或难治性或重叠性鼻炎的患病率正在上升,是一个不可忽视的社会经济负担。总体而言,尽管有社会医疗成本,但变应性鼻炎仍然被低估,控制不足且常常治疗不充分。
在这项意大利多中心观察性前瞻性研究中,我们评估了转诊至过敏中心的无哮喘既往诊断患者(>16岁)的AR控制情况。
研究有鼻炎症状且无哮喘的16岁以上男女患者。使用视觉模拟量表(VAS)和变应性鼻炎和哮喘控制测试(CARAT)作为患者报告结局。按照方案评估AR控制不佳的可能原因。
我们在实际环境中观察了250例患者:其中60%以上的患者AR控制不佳,只有约50%的患者使用多种药物,只有少数患者接受变应原免疫治疗。
在实际环境中进行的这项调查证实,AR总体控制不佳。VAS评估与结构化的CARAT问卷以及AR的相关症状密切相关。